Canadian Journal of Infectious Diseases and Medical Microbiology (Jan 2013)
The Impact of Serum Vancomycin Levels and Minimum Inhibitory Concentrations of Methicillin-Resistant Staphylococcus aureus on Mortality in Patients with Nosocomial Pneumonia
Abstract
BACKGROUND: Vancomycin is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections; however, treatment failure is not uncommon, even when the minimum inhibitory concentration (MIC) of the MRSA strain is within the susceptible range for vancomycin.